[HTML][HTML] Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
SP Lau, N van Montfoort, P Kinderman… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
[PDF][PDF] Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
SP Lau, N van Montfoort, P Kinderman, M Lukkes… - academia.edu
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpointblockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpointblockade immunotherapy. We hypothesized that a bimodal treatment …
[HTML][HTML] Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
SP Lau, N van Montfoort, P Kinderman… - … for ImmunoTherapy of …, 2020 - jitc.bmj.com
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
SP Lau, N van Montfoort… - Journal for …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
[PDF][PDF] Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
SP Lau, N van Montfoort, P Kinderman… - … for Pancreatic Ductal …, 2023 - core.ac.uk
Background: Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
[PDF][PDF] Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
SP Lau, N van Montfoort, P Kinderman, M Lukkes… - scholarlypublications …
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpointblockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpointblockade immunotherapy. We hypothesized that a bimodal treatment …
[PDF][PDF] Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
SP Lau, N van Montfoort, P Kinderman, M Lukkes… - pure.eur.nl
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpointblockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpointblockade immunotherapy. We hypothesized that a bimodal treatment …
[PDF][PDF] Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
SP Lau, N van Montfoort, P Kinderman, M Lukkes… - scholar.archive.org
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpointblockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpointblockade immunotherapy. We hypothesized that a bimodal treatment …
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
SP Lau, N van Montfoort, P Kinderman… - Journal for …, 2020 - search.proquest.com
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
SP Lau, N van Montfoort, P Kinderman… - … for Immunotherapy of …, 2020 - europepmc.org
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …